Search Results - "Hafkin, Barry"

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects by Eckburg, Paul B, Ge, Yigong, Hafkin, Barry

“…A multipart phase 1 study was conducted to determine the safety, tolerability, pharmacokinetics, and food effect of the novel oral oxazolidinone, MRX-I, in…”
Get full text

Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor by KAPLAN, Nachum, ALBERT, Monique, SCHMID, Molly B, THALAKADA, Rosanne, YETHON, Jeremy, PAULS, Henry W, AWREY, Donald, BARDOUNIOTIS, Elias, BERMAN, Judd, CLARKE, Teresa, DORSEY, Mandy, HAFKIN, Barry, RAMNAUTH, Jaillal, ROMANOV, Vladimir

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections by Dennis, L. Stevens, Daniel, Herr, Harry, Lampiris, John, Lee Hunt, Donald, H. Batts, Barry, Hafkin

“…Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant…”
Get full text

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity by KARLOWSKY, James A, KAPLAN, Nachum, HAFKIN, Barry, HOBAN, Daryl J, ZHANEL, George G

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Hematologic Effects of Linezolid: Summary of Clinical Experience by GERSON, Stanton L, KAPLAN, Sheldon L, BRUSS, Jon B, LE, Vu, ARELLANO, Felix M, HAFKIN, Barry, KUTER, David J

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies by Rubinstein, Ethan, Isturiz, Raul, Standiford, Harold C, Smith, Leon G, Oliphant, Thomas H, Cammarata, Sue, Hafkin, Barry, Le, Vu, Remington, Jack

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections by Stevens, D L, Smith, L G, Bruss, J B, McConnell-Martin, M A, Duvall, S E, Todd, W M, Hafkin, B

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis by Shoen, Carolyn, DeStefano, Michelle, Hafkin, Barry, Cynamon, Michael

“…The activity of contezolid (MRX-I) against clinical isolates of was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid…”
Get full text

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects by Kaplan, Nachum, Garner, Colin, Hafkin, Barry

“…[Display omitted] To investigate the absorption, distribution, metabolism and excretion of AFN-1252, a novel inhibitor of the essential FabI enzyme in…”
Get full text

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis by Almeida, Deepak, Li, Si-Yang, Lee, Jin, Hafkin, Barry, Mdluli, Khisimuzi, Fotouhi, Nader, Nuermberger, Eric L

“…Contezolid is a new oxazolidinone with and activity against comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less…”
Get full text

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen by Bulitta, Jürgen B, Hafkin, Barry, Fang, Edward

“…Abstract Background Contezolid (CZD) is a novel oral oxazolidnone with comparable activity and potentially improved safety compared to current oxazolidinones…”
Get full text

Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens by Bulitta, Jürgen B, Fang, Edward, Stryjewski, Martin E, Wang, Wen, Atiee, George J, Stark, Jeffrey G, Hafkin, Barry

“…Contezolid is a novel oxazolidinone antibiotic with a promising safety profile. Oral contezolid and its intravenous (IV) prodrug contezolid acefosamil (CZA)…”
Get full text

Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects by Hunt, Thomas, Kaplan, Nachum, Hafkin, Barry

“…Background: AFN-1252 is a novel inhibitor of FabI, which is essential in Staphylococcus spp. This study evaluated the safety, tolerability and pharmacokinetics…”
Get full text

Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects by Hafkin, Barry, Kaplan, Nachum, Hunt, Thomas L

“…AFN-1252 is a novel inhibitor of FabI, an essential enzyme in spp. This study was undertaken to assess the safety, tolerability and pharmacokinetic properties…”
Get full text

Corrigendum to “AFN-1252 in vitro absorption studies and pharmacokinetics following” [Eur. J. Pharm. 50 (3–4) (2013) 440–446] by Kaplan, Nachum, Garner, Colin, Hafkin, Barry

Get full text

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model by Banevicius, Mary A, Kaplan, Nachum, Hafkin, Barry, Nicolau, David P

“…AFN-1252, a new antimicrobial agent, specifically and potently inhibits fatty acid synthesis in Staphylococcus aureus. We characterized in vivo pharmacokinetic…”
Get full text

In vitro activity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics by Kaplan, Nachum, Awrey, Donald, Bardouniotis, Elias, Berman, Judd, Yethon, Jeremy, Pauls, Henry W, Hafkin, Barry

“…AFN-1252 is a novel inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252 exhibits typical MIC 90 values of ⩽0·015…”
Get full text

Pharmacokinetics, pharmacodynamics and efficacy of novel Fabl inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model by BANEVICIUS, Mary A, KAPLAN, Nachum, HAFKIN, Barry, NICOLAU, David P

Get full text

Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects by Hafkin, Barry, Berg, Jolene K, Kaplan, Nachum, Métral, Valérie Nicolas, Ménétrey, Annick, Alcorn, Harry, Wittke, Frederick

Get full text

In vitro activity (MICs and rate of kill) of AFN-1252, a novel Fabl inhibitor, in the presence of serum and in combination with other antibiotics by KAPLAN, Nachum, AWREY, Donald, BARDOUNIOTIS, Elias, BERMAN, Judd, YETHON, Jeremy, PAULS, Henry W, HAFKIN, Barry

Get full text